Selective Anti-Proliferation of HER2-Positive Breast Cancer Cells by Anthocyanins Identified by High-Throughput Screening

Liu, Weihua; Xu, Jinmei; Wu, Shaoping; Liu, Yilun; Yu, Xiaoping; Chen, Juan; Tang, Xi; Wang, Zhi; Zhu, Xiaohu; Li, Xin
December 2013
PLoS ONE;Dec2013, Vol. 8 Issue 12, p1
Academic Journal
Overexpressed Human epidermal growth factor receptor 2 (HER2) drives the biology of 20% breast cancer and is a prediction of a poor prognosis for patients. HER2-targeted therapies significantly improve outcomes for HER2-positive patients. Traditional Chinese herbs/medicines have been used to treat breast cancer patients including HER2-positive patients in Asia for decades. Although the traditional medicines demonstrate efficacy in clinics for HER2-positive patients, the mechanism is largely unknown. In this article, we screened a 10,000 natural product library in 6 different cell lines representing breast cancer, and assessed the ability of each drug to cause cytotoxicity through a high-throughput screening approach. We have identified eight natural compounds that selectively inhibit the proliferation of HER2-positive cells. Two of the hit compounds, peonidin-3-glucoside and cyaniding-3-glucoside, are both extracts from black rice. They inhibit the phospho-HER2 and phospho-AKT and were confirmed to induce HER2-psotive breast cancer cells apoptosis both in vitro and in vivo. Peonidin-3-glucoside and cyaniding-3-glucoside treatments significantly reduced the tumor size and volume in vivo compared to the control group. There is no significant difference of antitumorgenic effects between peonidin-3-glucoside and cyaniding-3-glucoside treatments.


Related Articles

  • Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis. Petrelli, F.; Barni, S. // Medical Oncology;Dec2012, Vol. 29 Issue 4, p2586 

    High levels of human epidermal growth receptor 2 (HER2) expression are associated with recurrence and death in breast cancer (BC) patients. We have performed a systematic review and meta-analysis in order to evaluate the prognosis for HER2+ pT1a-bN0M0 BC patients. A search of PubMed and Embase...

  • Young breast cancer: A single center experience. Gogia, A.; Raina, V.; Deo, S. V. S.; Shukla, N. K.; Mohanti, B. K. // Indian Journal of Cancer;Oct-Dec2014, Vol. 51 Issue 4, p604 

    Background: Breast cancer in women aged less than 35 years is uncommon and accounts for 1-2% of all breast cancer in the West. There is a paucity of data on young breast cancer from India. The aim of this study was to analyze the clinical, pathological, prognostic factors and...

  • The distinct clinicopathological and prognostic implications of PIK3CA mutations in breast cancer patients from Central China. Wu, Haibo; Wang, Wei; Du, Jun; Li, Hong; Wang, Huogang; Huang, Liangliang; Xiang, Hang; Xie, Jing; Liu, Xiaoli; Li, Heng; Lin, Wenchu // Cancer Management & Research;Feb2019, Vol. 11, p1473 

    Purpose: The mutation status and prognostic value of PIK3CA in breast cancer were widely investigated, which showed significant difference among the patients from vast areas around the world. In this study, the frequency, distribution, bias, and burden of PIK3CA mutations and their relationships...

  • Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer. Wishart, Gordon C.; Rakha, Emad; Green, Andrew; Ellis, Ian; Ali, Hamid R.; Provenzano, Elena; Blows, Fiona M.; Caldas, Carlos; Pharoah, Paul D. P. // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background PREDICT (www.predict.nhs.uk) is a prognostication and treatment benefit tool for early breast cancer (EBC). The aim of this study was to incorporate the prognostic effect of KI67 status in a new version (v3), and compare performance with the Predict model that includes HER2 status...

  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Cardoso, F.; Costa, A.; Norton, L.; Senkus, E.; Aapro, M.; André, F.; Barrios, C. H.; Bergh, J.; Biganzoli, L.; Blackwell, K. L.; Cardoso, M. J.; Cufer, T.; El Saghir, N.; Fallowfield, L.; Fenech, D.; Francis, P.; Gelmon, K.; Giordano, S. H.; Gligorov, J.; Goldhirsch, A. // Annals of Oncology;Oct2014, Vol. 25 Issue 10, p1871 

    No abstract available.

  • Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Tsang, R Y; Finn, R S // British Journal of Cancer;1/3/2012, Vol. 106 Issue 1, p6 

    The use of trastuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) alteration present in 25 to 30% of breast cancers, has been associated with improved survival outcomes in both the adjuvant and metastatic settings. However, despite the robust clinical...

  • Biomarkers characterization of circulating tumour cells in breast cancer patients.  // Breast Cancer Research;2012, Vol. 14 Issue 1, pR71 

    The article focuses on a study that analyzes the expression of epidermal growth factor receptor (EGFR) in circulating tumor cells (CTCs) of patients with breast cancer. The researchers objective was to distinguish the set of biomarkers in CTCs and correlate it with clinical-pathological...

  • Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Rakha, E A; Tan, P H; Varga, Z; Tse, G M; Shaaban, A M; Climent, F; van Deurzen, C H M; Purnell, D; Dodwell, D; Chan, T; Ellis, I O // British Journal of Cancer;1/20/2015, Vol. 112 Issue 2, p283 

    Background:Metaplastic breast carcinoma (MBC) is a rare type of breast cancer that has basal-like characteristics and is perceived to have poorer prognosis when compared with conventional no specific type/ductal carcinomas (ductal/NST). However, current data on MBC are largely derived from small...

  • Vimentin as a poor prognostic factor for triple-negative breast cancer. Yamashita, Nami; Tokunaga, Eriko; Kitao, Hiroyuki; Hisamatsu, Yuichi; Taketani, Kenji; Akiyoshi, Sayuri; Okada, Satoko; Aishima, Shinichi; Morita, Masaru; Maehara, Yoshihiko // Journal of Cancer Research & Clinical Oncology;May2013, Vol. 139 Issue 5, p739 

    Purpose: Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, is a highly heterogeneous disease. Recent studies suggest that there are links between TNBC and the epithelial-mesenchymal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics